May 18th Bloodbath: M&A Juice vs. Clinical Trial Failure
The Pulse
Markets are red. $SPY at 735.95, $QQQ bleeding out at 702.11. The VIX is chilling at 18.41, which is suspicious given the carnage in individual names. If you’re playing 0DTEs today, you’re either eating or getting crushed by theta.
Market Data Summary
| Ticker | Price | Change % | RVol |
|---|---|---|---|
| $RAMP | 37.80 | +27.44% | 11.03 |
| $D | 67.27 | +8.97% | 4.10 |
| $REGN | 628.59 | -9.98% | 2.84 |
| $POET | 13.475 | -15.62% | 1.74 |
| $AEHR | 82.99 | -16.59% | 0.90 |
The M&A Mirage: $RAMP and $D
Publicis is buying $RAMP for $2.55B. RVol is sitting at 11.03—that’s pure institutional panic/FOMO buying. Don’t chase the gap; the move is already baked in. Similarly, $D is getting sucked into the NextEra maw for $67B. Utility M&A is boring, but the volume spike confirms the sector rotation is real. If you’re long, take the profit. Don’t be the bagholder waiting for the deal to close.
The Knife Catchers: $REGN and $AEHR
$REGN is down 10% after a melanoma drug-trial miss. This is a classic biotech wipeout. Trial failure is the ultimate binary event. You either have the drug or you don’t. Analysts are already downgrading, and the IV is likely pumped to the moon. Avoid the long side here; the knife is still spinning.
$AEHR is getting dismantled, down 16.59%. Valuation questions surrounding AI demand are hitting the mid-caps hard. The market is tired of 'AI potential'—show me the revenue or get off the stage. The 0.9 RVol suggests the selling is retail capitulation rather than heavy institutional exit, but the chart is broken.
The Play
Watch $RAMP for a potential momentum fade if the retail crowd tries to squeeze the remaining float. Otherwise, stay cash-heavy or fade the tech bounce. $QQQ sub-700 is the line in the sand for the bulls. If it breaks, don't try to be a hero.
Data Source: Market Close 2026-05-18, proprietary feed.
Disclaimer: Eachi Alpha provides independent financial analysis based on algorithmic market data. This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading securities involves significant risk. Eachi Alpha is not responsible for any financial losses or damages resulting from the use of this information. Always perform your own due diligence before making investment decisions.